Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma

European Journal of Gynaecological Oncology

Volumn 25, Issue 4, 2004, Pages 449-452

  Piura, B ^a   Rabinovich, A ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

CA 125; Chemotherapy; Gemcitabine; Ovarian carcinoma; Toxicity

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CHILL; CLINICAL ARTICLE; CLINICAL EXAMINATION; DRUG DOSE REGIMEN; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; HUMAN; ISRAEL; LEUKOPENIA; NEUTROPENIA; OVARY CARCINOMA; PERITONEUM CANCER; RADIOLOGY; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

ADULT; AGED; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3242655715     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. McGuire W.P., Ozols R.F.: "Chemotherapy of advanced ovarian cancer". Semin. Oncol., 1998, 25, 340.
2. Lund B., Hansen O.P., Neijt J.P., Theilade K., Hansen M.: "Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients". Anticancer Drugs, 1995, 6 (suppl. 6), 61.
3. Shapiro J.D., Millward M.J., Rischin D., Michael M., Walcher, V., Francis P.A. et al.: "Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel". Gynecol. Oncol., 1996, 63, 89.
4. Friedlander M., Millward M.J., Bell D., Bugat R., Harnett P., Moreno J.A. et al.: "A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer". Ann. Oncol., 1998, 9, 1343.
5. von Minckwitz G., Bauknecht T., Visseren-Grul C.M., Neijt J.P.: "Phase II study of gemcitabine in ovarian cancer". Ann. Oncol., 1999, 10, 853.
6. Silver D.F., Piver M.S.: "Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum". Am. J. Clin. Oncol., 1999, 22, 450.
7. th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May 20-23, 2000, Abstract No. 1603.
8. Markman M., Webster K., Zanotti K., Kulp B., Peterson G., Belinson J.: "Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer". Gynecol. Oncol., 2003, 90, 593.
9. Bilgin T., Ozalp S., Yalcin O.T., Zorlu G., Vardar M.A., Ozerkan K.: "Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients". Eur. J. Gynaecol. Oncol., 2003, 24, 169.
10. D'Agostino G., Amant F., Berteloot P., Scambia G., Vergote I.: "Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer". Gynecol. Oncol., 2003, 88, 266.
11. Levin L., Hryniuk W.M.: "Dose intensity analysis of chemotherapy regimens in ovarian carcinoma". J. Clin. Oncol., 1987, 5, 756.
12. Levin L., Hryniuk W.M.: "The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer". Semin. Oncol., 1987, 14 (suppl. 4), 12.
13. Hansen S.W.: "Gemcitabine in the treatment of ovarian cancer". Int. J. Gynecol. Cancer, 2001, 11 (suppl. 1), 39.
14. Common Terminology Criteria for Adverse Events, Version 3.0, Revised June 10, 2003, National Cancer Institute, http://ctep.cancer.gov/forms/CTCAEv3.pdf.
15. Cesano A., Lane S.R., Poulin R., Ross G., Fields S.Z.: "Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients". Int. J. Oncol., 1999, 15, 1233.
16. Nielsen H.A., Nielsen D., Engelholm S.A.: "Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer". Gynecol. Oncol., 2000, 77, 383.